Linked Life Data

15917401

Source:http://linkedlifedata.com/resource/pubmed/id/15917401

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2005-6-29
pubmed:abstractText
Infant botulism causes acute bulbar dysfunction, weakness, and respiratory failure in infants living in endemic regions of the United States. Until Food and Drug Administration approval of botulism immune globulin (BIG) in October 2003, management of infant botulism had changed little since the 1970s. Currently, IV therapy with BIG is advised to shorten the duration and diminish the potential complications of the disorder. This review describes two decades of experience with infant botulism and provides a contemporary perspective on the role and benefit of BIG.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1526-632X
pubmed:author
pubmed:issnType
Electronic
pubmed:day
28
pubmed:volume
64
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2029-32
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Infant botulism in the age of botulism immune globulin.
pubmed:affiliation
Division of Pediatric Neurology, Department of Pediatrics, The University of Utah, Primary Children's Medical Center, Salt Lake City, UT, USA. joel.thompson@hsc.utah.edu
pubmed:publicationType
Journal Article, Review